HSBC Initiates Coverage on Haleon (LON:HLN)

HSBC started coverage on shares of Haleon (LON:HLN) in a research report issued on Thursday, MarketBeat reports. The firm set a “buy” rating on the stock.

Separately, Barclays lowered their target price on shares of Haleon from GBX 390 ($4.85) to GBX 383 ($4.77) and set an “overweight” rating for the company in a research note on Tuesday, April 9th.

Haleon Stock Up 1.4 %

Haleon stock opened at GBX 325.80 ($4.06) on Thursday. The firm has a market cap of £29.75 billion and a price-to-earnings ratio of 2,961.82. Haleon has a 52-week low of GBX 306.80 ($3.82) and a 52-week high of GBX 357.65 ($4.45). The company has a debt-to-equity ratio of 57.42, a quick ratio of 0.93 and a current ratio of 1.04. The firm has a 50 day moving average price of GBX 324.40 and a two-hundred day moving average price of GBX 326.71.

Insider Activity

In related news, insider Tobias Hestler sold 23,564 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of GBX 329 ($4.10), for a total transaction of £77,525.56 ($96,508.85). 22.53% of the stock is currently owned by company insiders.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.